The Effect of Progesterone on the Haemostatic Mechanism

M Blombäck; B-M Landgren; Y Stiernholm; O Andersson

doi:10.1055/s-0038-1655915

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1997; 77(01): 105-108
DOI: 10.1055/s-0038-1655915

Coagulation

Schattauer GmbH Stuttgart

The Effect of Progesterone on the Haemostatic Mechanism

Authors

M Blombäck

¹The Department of Laboratory Medicine/Blood Coagulation Research, University of Stockholm, Sweden
B-M Landgren

²The Department of Woman and Child Health, Division for Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
Y Stiernholm

²The Department of Woman and Child Health, Division for Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden
O Andersson

³The Department of Psychology, University of Stockholm, Sweden

Abstract

PDF Download

Summary

The hemostatic effect of progesterone administered vaginally at a dose of 100 mg twice a day throughout one menstrual cycle was investigated and compared with the coagulation factors in one untreated normal menstrual cycle in 15 women. The progesterone treatment resulted in a 20-fold progesterone rise in the early follicular phase from 1.2 nmol/1 in the pretreatment control cycle to levels between 26 and 29 nmol/1 during treatment. Ovulation was completely suppressed in seven women while eight women showed a slight rise in progesterone on treatment days 20 to 25 not compatible with the rise which could have been expected if ovulation had occurred. The effects found on haemostasis during progesterone treatment varied with the menstrual cycle and were so small that they could as well be due to chance and not to treatment.

PDF (1137 kb)

References

References
1 Bonnar J. Coagulation effects of oral contraception. Am J Obstet Gynecol 1987; 157: 1042-1048
2 Robinson GE. Low dose combined oral contraceptives. Br J Obstet Gynaecol 1994; 101: 1036-1041
3 Jespersen J, Petersen KR, Skouby SO. Effects of newer contraceptives on the inhibition of coagulation and fibrinolysis in relation to dosage and type of steroid. Am J Obstet Gynecol 1990; 163: 396-403
4 Kooistra T, Bosma JP, Jespersen J, Kluft C. Studies on the mechanism of action of oral contraceptives with regard to fibrinolytic variables. Am J Obstet Gynecol 1990; 163: 404-413
5 Fotherby K. The progestogen-only pill and thrombosis. Br J Fam Plann 1989; 15: 83-85
6 Jick H, Jick SS, Gurewich V, Myers W, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with progestagen components. Lancet 1995; 346: 1589-1592
7 World Health Organization, Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low estrogen oral contraceptives on venous thrombotic disease. Lancet 1995; 346: 1582-1588
8 World Health Organization, Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1581
9 Bloemenkamp KWM, Roosendaal FR, Helmerhaust FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third generation progestagen. Lancet 1995; 346: 1593-1596
10 Weiss N. Third-generation oral contraceptives: how risky?. Lancet 1994; 346: 1570
11 Aune B, Höie KE, Öian P, Holst N, Østerud B. Does ovarian stimulation for in-vitro fertilization induce a hypercoagulable state?. Hum Reprod 1991; 07: 925-927
12 Bremme K, Wramsby H, Andersson O, Wallin M, Blombäck M. Do lowered factor VII levels at extremely high endogenous oestradiol levels protect against thrombin formation?. Blood Coag Fibrinolysis 1994; 05: 205-210
13 Sitruk-Ware R, Bricarie C, de LignersB, Yaneva H, Mauvais-Jarvis P. Oral micronized progesterone. Contraception 1987; 36: 373-402
14 Landgren B-M, Unden A-L, Diczfalusy E. Hormonal profile of the cycle in 68 normally menstruating women. Acta Endocrinol 1980; 94: 89-98
15 Oswaldsson U, Wilson S, Rosén S. A simple chromogenic assay for the determination of Factor VII in microtiter plates. Thromb Haemost. 1977; 54: 26 (abstr. 153)
16 Rosén S, Andersson M, Blombäck M, Hägglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjörin E, Vinazzer H. Clinical application of a chromogenic substrate method for determination of Factor VIII activity. Thromb Haemost 1985; 54: 818-823
17 Abildgaard U, Lie M, Ödegaard OR. Antithrombin heparin co-factor assay with new chromogenic substrates S-2238 and Chromozym TH. Thromb Res 1977; 01: 549-553
18 Ödegaard OR, Try K, Andersson TR. Protein C: An automated activity assay. Haemostasis 1987; 17: 109-113
19 Chmielewska J, Wiman B. Determination of tissue plasminogen activator and its “fast” inhibitor in plasma. Clin Chem 1986; 32: 482-485
20 Vermylen C, de VrekerRA, Verstraete M. A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT) test. Clin Chim Acta 1963; 08: 418-424
21 Silveira AMV, Yamamoto T, Adamson L, Hessel B, Blombäck B. Application of an enzyme-linked immunosorbent assay (ELISA) to von Willebrand factor (vWF) and its derivatives. Thromb Res 1986; 43: 91-102
22 Pelzer H, Schwarz A, Heimburger N. Determination of human thrombinantithrombin III complex in plasma with enzyme-linked immunosorbent assay. Thromb Haemost 1988; 59: 101-106
23 Hahn L, Cederblad G, Rybo G, Pehrsson N-G, Korsan-Bengtsen K. Blood coagulation, fibrinolysis and plasma proteins in women with normal and with excessive menstrual blood loss. Br J Obstet Gynaecol 1976; 83: 974-980
24 Jesperson J, Kluft C. Inhibition of tissue-type plasminogen activator in plasma of women using oral contraceptives and in normal women during a menstrual cycle. Thromb Haemost 1986; 55: 388-389
25 Lebech A-M, Kjaer A, Lebech PE. Metabolic changes during the normal menstrual cycle: A longitudinal study. Am J Obstet Gynecl 1990; 163: 414-416
26 Cederblad G, Hahn L, Korsan-Bengtsen K, Pehrsson NG, Rybo G. Variations in blood coagulation, fibrinolysis, platelet function and various plasma proteins during the menstrual cycle. Haemostasis 1977; 06: 294-302
27 Jespersen J. Sequential study of plasma euglobin fibrinolytic activity during the normal menstrual cycle and in women on oral contraceptives low in estrogen. Gynecol Obstet Invest 1983; 15: 266-274
28 Siegbahn A, Odlind V, Hedner U, Venge P. Coagulation and fibrinolysis during the normal menstrual cycle. Upsala J Med Sci 1989; 94: 137-152
29 Blombäck M, Eneroth P, Landgren B-M, Lagerström M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992; 67: 70-75
30 Mauvais-Jarvis P. Progesterone and progestins: A general overview. In: Progesterone and Progestins. Wayne-Bardin C, Milgrom E, Mauvais-Jarvis P. (eds). Raven Press; New York: 1983. pp 1-16
31 Nahaul K, Dehennin L, Jondet I, Roger M. Profiles of plasma progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. Maturitas 1993; 16: 185-202